← SynDRA
TAVABOROLE
SynDRA canonical compound SYN0006302 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Mechanism of action | leucyl-tRNA synthetase inhibitor |
|---|
| Indication | onychomycosis |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CA1
- CA2
- CAN2
- CDC60
- Stap-coc leuS
Mechanisms of action (all sources)
- leucyl-tRNA synthetase inhibitor
- Stap-coc leuS INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- HTR2B
- SLC6A4
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- KCNH2
- HTR1A
- ADORA3
- HRH3
- HDAC6
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Drug classes
- Protein Synthesis Inhibitors
- Anti-Infective Agents
- Antifungal Agents
- Oxaborole Antifungal
ATC classes
- D01A · ANTIFUNGALS FOR TOPICAL USE
Cross-references
Synonyms
- KERYDIN
- Kerydin
- AN 2690
- kerydin
- AN2690
- Tavaborol
- AN-2690
- SCH-900340
- AN-2690)
- Topical antifungal (onychomycosis), Merck & Co
- Trichophyton-targeting antifungal (onychomycosis), Merck & Co
- Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
- Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor
- Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
- SCH 900340
- K124A4EUQ3
- 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
- 5-fluoro-2,1-benzoxaborol-1(3H)-ol
- 2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-
- tavaborol
- CHEBI:77942
- tavaborolum
- RefChem:58437
- DTXCID5092379
- D01AE24
- TAVABOROLE topical solution, 5%
- 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
- MFCD10699483
- 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol
- Tavaborole [USAN]
- Tavaborole (>90%)
- 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole
- Tavaborole (USAN)
- Tavaborole [USAN:INN]
- UNII-K124A4EUQ3
- p-fluorbenzoxaborole
- Kerydin (TN)
Reported adverse events
- Application site dermatitis
- Application site erythema
- Hypersensitivity
- Application site exfoliation
Look up TAVABOROLE in the interactive SynDRA portal →